Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and St Hilda's College are delighted to announce the creation of a new Chair of Clinical Therapeutics thanks to initial, generous, philanthropic support from Professor John Climax. The donation was confirmed at a signing ceremony on Friday 15th December 2017.

Left to Right: Sir Gordon Duff, Principal of St Hilda's College; Professor John Climax; Professor Andrew Carr, Head of NDORMS; Dr Sarah Norman, Senior Tutor, St Hilda's College. Photo credit John Cairns

Through the establishment of this Chair, Oxford will be in a position to address a significant challenge facing universities today: how to translate novel therapies quickly and sustainably from laboratory to clinic.

Under their leadership, the University will establish a new Centre for Clinical Therapeutics, based within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), headed by Professor Andrew Carr. Through this centre, the Chair will work to develop close partnerships within Oxford, and more widely with the pharmaceutical, biotechnology and diagnostics industries, in order to drive new drug treatments through early phase clinical trials.

In addition to funding the Chair, the gift will be used to endow new Fellowships in Clinical Therapeutics. This will open the doors of opportunity to many early and mid-career clinical scientists, enabling them to develop their expertise and practical experience in early phase clinical trials at Oxford. Both the Chair and Fellowships will be associated with St Hilda's College.

Read more (on Oxford Thinking website)      

Similar stories

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.

World Osteoporosis Day 2022

A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.